Mar 8 |
Q4 2023 Phathom Pharmaceuticals Inc Earnings Call
|
Mar 7 |
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript
|
Mar 7 |
Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ...
|
Mar 7 |
Phathom Pharmaceuticals Non-GAAP EPS of -$0.80 beats by $0.20, revenue of $0.68M beats by $0.3M
|
Mar 7 |
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Mar 7 |
Earnings Scheduled For March 7, 2024
|
Feb 29 |
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
|
Feb 13 |
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
|
Jan 31 |
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
|
Jan 28 |
With 47% ownership, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has piqued the interest of institutional investors
|